COVID-19 and other diagnostic testing for patients with NP swabs and BAL performed within 7 days
| COVID-19 and other testing characteristics | Total (N=42) |
| No. of NP swabs performed | |
| Total | 82 |
| Within 1 week and closest to BAL | 42 |
| No. of patients with single or multiple NP swabs within 7 days of BAL | |
| 1 | 14 (33.3) |
| 2 | 16 (38.1) |
| ≥3 | 12 (28.6) |
| NP swab testing platforms (%) within 1 week and closest to BAL | |
| Cepheid Xpert | 24 (57.1) |
| DiaSorin | 8 (19.0) |
| Abbott ID Now | 3 (7.1) |
| Roche cobas 6800 | 4 (9.5) |
| Panther Fusion | 1 (2.3) |
| Missing (other institution) | 2 (4.8) |
| No. of BAL performed for COVID-19 testing | |
| Total | 53 |
| Within 7 days of NP swab | 42 |
| BAL testing platforms within 7 days of NP swab (%) | |
| Abbott Alinity | 1 (2.4) |
| Centers for Disease Control and Prevention | 26 (61.9) |
| Cepheid Xpert | 7 (16.7) |
| Roche cobas 6800 | 6 (14.3) |
| Panther Fusion | 2 (4.8) |
| Days between symptom onset and BAL in COVID-19 confirmed patients, median (Q1–Q3) | n=13 14 (8–18) |
| Days between NP swab and BAL performed within 7 days, median (Q1–Q3) | 1 (0–4) |
| Positive BAL cultures other than COVID-19 | |
| Bacterial, n (%) | 3 (7.1) |
| Staphylococcus aureus | 2 (4.8) |
| Pseudomonas aeruginosa | 1 (2.4) |
| Fungal, n (%)—Aspergillus fumigatus | 1 (2.4) |
| Acid fast bacilli, n (%)—Mycobacterium avium | 1 (2.4) |
| Pneumocystis jirovecii PCR, n (%) | 1 (2.4) |
BAL, bronchoalveolar lavage; NP, nasopharyngeal.